|16 August 2016|
World-leading industrial biotech company Ingenza has secured €50,000 of funding to progress its novel biomanufacturing platform. The synthetic biology-driven platform is designed to enable biotech enterprises to more easily develop therapies for currently unmet clinical needs.
The EU H2020 SME Instrument funding will support its pioneering SYNBIOMAN project which aims to close the gap from lab to market by developing GMP biomanufacturing capabilities that target the production of therapeutic proteins.
Dr David McElroy, Chief Business Officer at Ingenza, said: “We are delighted to have secured EU H2020 SME Instrument support for this project. The Horizon 2020 programme receives thousands of funding applications each year, and fewer than 5% of applicants are successful. It is a real achievement for our scientific research to be recognised in this way.”
Successful completion of the Phase 1 study could open the door to additional funding for Phase 2, valued at €2.5 million.